These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 23096741)

  • 1. [Peritoneal carcinomatosis from ovarian cancer: role of 18F-FDG-PET/CT and CA125].
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Stabile Ianora AA; Giganti M; Niccoli Asabella A
    Recenti Prog Med; 2012 Nov; 103(11):510-4. PubMed ID: 23096741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue.
    Lopez-Lopez V; Cascales-Campos PA; Gil J; Frutos L; Andrade RJ; Fuster-Quiñonero M; Feliciangeli E; Gil E; Parrilla P
    Eur J Radiol; 2016 Oct; 85(10):1824-1828. PubMed ID: 27666623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peritoneal carcinomatosis in patients with ovarian cancer: enhanced CT versus 18F-FDG PET/CT.
    Kim HW; Won KS; Zeon SK; Ahn BC; Gayed IW
    Clin Nucl Med; 2013 Feb; 38(2):93-7. PubMed ID: 23334121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels.
    Palomar A; Nanni C; Castellucci P; Ambrosini V; Montini GC; Allegri V; Pettinato C; Al-Nahhas A; Soriano A; Grassetto G; Rubello D; Fanti S
    Mol Imaging Biol; 2012 Feb; 14(1):123-9. PubMed ID: 21240639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
    Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peritoneal carcinomatosis from ovarian cancer: the role of CT and [¹⁸F]FDG-PET/CT.
    Funicelli L; Travaini LL; Landoni F; Trifirò G; Bonello L; Bellomi M
    Abdom Imaging; 2010 Dec; 35(6):701-7. PubMed ID: 19784697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The maximum standardized uptake value and extent of peritoneal involvement may predict the prognosis of patients with recurrent ovarian cancer after primary treatment: A retrospective clinical study.
    Jiang Y; Hou G; Wu F; Zhu Z; Zhang W; Cheng W
    Medicine (Baltimore); 2020 Feb; 99(8):e19228. PubMed ID: 32080121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of peritoneal carcinomatosis extent diagnosis by initial FDG PET CT in epithelial ovarian cancer: A multicentre study of the FRANCOGYN research group.
    Delvallée J; Rossard L; Bendifallah S; Touboul C; Collinet P; Bricou A; Huchon C; Lavoue V; Body G; Ouldamer L
    J Gynecol Obstet Hum Reprod; 2020 Nov; 49(9):101867. PubMed ID: 32663654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
    Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
    Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125].
    García Velloso MJ; Boán García JF; Villar Luque LM; Aramendía Beitia JM; López García G; Richter Echeverría JA
    Rev Esp Med Nucl; 2003; 22(4):217-23. PubMed ID: 12846945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peritoneal carcinomatosis in primary ovarian cancer staging: comparison between MDCT, MRI, and 18F-FDG PET/CT.
    Schmidt S; Meuli RA; Achtari C; Prior JO
    Clin Nucl Med; 2015 May; 40(5):371-7. PubMed ID: 25783507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalities.
    Antunovic L; Cimitan M; Borsatti E; Baresic T; Sorio R; Giorda G; Steffan A; Balestreri L; Tatta R; Pepe G; Rubello D; Cecchin D; Canzonieri V
    Clin Nucl Med; 2012 Aug; 37(8):e184-8. PubMed ID: 22785525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.
    Palomar Muñoz A; Cordero García JM; Talavera Rubio MDP; García Vicente AM; Pena Pardo FJ; Jiménez Londoño GA; Soriano Castrejón Á; Aranda Aguilar E
    Medicine (Baltimore); 2018 Apr; 97(17):e0098. PubMed ID: 29702969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal carcinomatosis: role of (18)F-FDG PET.
    Turlakow A; Yeung HW; Salmon AS; Macapinlac HA; Larson SM
    J Nucl Med; 2003 Sep; 44(9):1407-12. PubMed ID: 12960184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose ([
    Palomar Muñoz A; Cordero García JM; Talavera Rubio P; García Vicente AM; González García B; Bellón Guardia ME; Soriano Castrejón Á; Aranda Aguilar E
    Med Clin (Barc); 2018 Aug; 151(3):97-102. PubMed ID: 29276012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
    Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
    Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
    Bhosale P; Peungjesada S; Wei W; Levenback CF; Schmeler K; Rohren E; Macapinlac HA; Iyer RB
    Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extraovarian primary peritoneal carcinoma: staging with 18F-FDG PET/CT.
    Rakheja R; Makis W; Hickeson M
    Abdom Imaging; 2012 Apr; 37(2):304-8. PubMed ID: 21394599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of PET/CT in peritoneal carcinomatosis from colorectal cancer.
    Bamba Y; Itabashi M; Kameoka S
    Hepatogastroenterology; 2012; 59(117):1408-11. PubMed ID: 22094993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.